Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590628 · ClinicalTrials.gov registry record · Phase 1
Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
A Phase 1 study, sponsored by Gamida Cell.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01590628 is a Phase 1 study that has completed, run by Gamida Cell. The registered enrollment target is 16 participants.
The verdict
NCT01590628, a Phase 1 study, has completed, sponsored by Gamida Cell.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
Interventions
- DRUG NiCord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-09 |
| Est. Completion | 2019-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590628
The ClinicalTrials.gov registry entry for NCT01590628 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gamida Cell, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NiCord is the first listed.
NCT01590628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01590628 about?
NCT01590628 is a clinical study titled "Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies". Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
What is the current status of trial NCT01590628?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2012-09. Estimated completion is 2019-10.
What interventions are being tested in trial NCT01590628?
The interventions under investigation include: NiCord (DRUG).
Who is sponsoring clinical trial NCT01590628?
This trial is sponsored by Gamida Cell, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.